SuperworthExelixis EXEL
- Market cap
- $16B
- PE
- 20.3×
- 9y median 22.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.6×
- EV/EBIT
- 15.4×
- Revenue, 12 months
- $2.4B
- +9% on a year ago
- Net margin
- 35.3%
- Free cash flow yield
- 7.3%
Exelixis trades at 20.3× trailing earnings, near its ten-year median. Revenue was $2.4B over the last twelve months, up 9% on a year earlier with a 35% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $471.9M+15% | $479.7M+13% | $425.2M+4% | $637.2M+36% | $539.5M+14% | $566.8M+18% | $555.4M+31% | $568.3M−11% | $597.8M+11% | $598.7M+6% | $610.8M+10% | $628.7M+11% | |
| Cost of revenue | $18.8M+23% | $21.8M+37% | $21.3M+49% | $17.7M−0% | $17.3M−8% | $20M−8% | $19.2M−10% | $19.5M+10% | $18.6M+7% | $26.5M+33% | $20M+4% | $20.7M+6% |
| Gross profit | $453.1M+14% | $457.9M+12% | $404M+2% | $619.5M+37% | $522.2M+15% | $546.8M+19% | $536.3M+33% | $548.8M−11% | $579.2M+11% | $572.2M+5% | $590.9M+10% | $608M+11% |
| R&D | $332.6M+67% | $244.7M−27% | $227.7M−3% | $211.1M−9% | $222.6M−33% | $249M+2% | $212.2M−7% | $200.4M−5% | $199.2M−11% | $213.2M−14% | $199.9M−6% | $212M+6% |
| SG&A | $138.1M+20% | $131.4M+10% | $114M−13% | $132M−7% | $111.8M−19% | $134.3M+2% | $137.2M+20% | $134.9M+2% | $123.7M+11% | $123M−8% | $139.6M+2% | $147.6M+10% |
| −$17.6M | $81.8M | $29.5M+2% | $275.9M+254% | $136.1M | $163.2M+100% | $186.9M+534% | $213.6M−23% | $236.5M+74% | $235.2M+44% | $251.3M+35% | $248.4M+16% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $5.8M−94% | $103M | $49.3M+2% | $292.8M+192% | $154.8M+2560% | $184.8M+79% | $205.7M+318% | $230.4M−21% | $252.4M+63% | $252.7M+37% | $267.7M+30% | $262.7M+14% |
| $4.8M−75% | $17.5M | $11.9M+45% | $66.7M+247% | $36.8M+670% | $44.9M+156% | $46.1M+286% | $45.6M−32% | $58.8M+60% | $8.2M−82% | $57.2M+24% | $50.6M+11% | |
| Net income | $1M−99% | $85.5M | $37.3M−7% | $226.1M+179% | $118M+11233% | $139.9M+64% | $159.6M+328% | $184.8M−18% | $193.6M+64% | $244.5M+75% | $210.5M+32% | $212.1M+15% |
| $0.00 | $0.27 | $0.12+0% | $0.77+208% | $0.40 | $0.48+78% | $0.55+358% | $0.65−16% | $0.69+73% | $0.88+83% | $0.79+44% | $0.82+26% | |
| 319.2M−2% | 313M−3% | 305.5M−6% | 294M−10% | 291.5M−9% | 293.7M−6% | 288.2M−6% | 284.4M−3% | 278.5M−4% | 276.3M−6% | 267.3M−7% | 259.7M−9% |
Revenue: Q1 FY10: 6 months less the 3 months printed beside them.
Gross profit: 50 periods, Q1 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY10: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 13 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY10 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY11 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Exelixis' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| Peer median | $19B | 37.6× | 42.8× | 26.7× | 7.5× | +25% | 22.9% |
More on Exelixis
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 29Biotech stocks with the highest profit margins
- #3of 18Biotech stocks with the highest free cash flow yield
- #6of 17Biotech stocks with the lowest EV/EBIT
- #6of 16Biotech stocks with the lowest PE ratio
- #8of 14Biotech stocks with the fastest earnings growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .